The Microkeratome Market, estimated at USD 1,103.1 Mn in 2025, is expected to exhibit a CAGR of 10.1% and reach USD 2,163.3 Mn by 2032.
The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.
The key market players are focused on adopting growth strategies, such as product launch as well as partnerships, which will drive the global microkeratome market growth during the forecast period. For instance, on February 1, 2025, Bausch & Lomb Incorporated or its affiliates, an eye health company, and Modulight Corporation, a biomedical laser company, announced that the U.S. Food and Drug Administration (FDA) has approved ML6710i photodynamic laser for equivalent use with Bausch + Lomb’s VISUDYNE (verteporfin for injection) Photodynamic Therapy (PDT) for the treatment of patients with predominantly classic subfoveal choroidal neovascularization, or the creation of abnormal choroidal blood vessels, due to Age-related Macular Degeneration (AMD).
Global Microkeratome Market - Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation of drugs from one place to another.
COVID-19 had a negative impact on the global microkeratome market. The COVID-19 pandemic resulted in the cancellation of all elective procedures. The growth of the global microkeratome market is witnessing a decline due to the outbreak of the COVID-19. This is mainly because ophthalmologists are not seeing patients with active COVID-19 disease and the footfall has also decreased in hospitals and diagnostic centers. It is estimated that the methods of surgical remodeling of cataract or cornea will transform post pandemic. Initially, the government's implemented lockdowns led to a drop in footfall in clinics and hospitals for eye care and the cancellation or postponement of many procedures. For instance, in January 2025 , according to an article published in the JAMA Ophthalmology Journal, in school-based photo screenings conducted in China, children between the age of 6 and 8 years who were kept at home during the COVID-19 pandemic suffered significant myopic changes. Therefore, the initial decline in ophthalmic procedures is expected to cover up with ease in restriction and decline in COVID-19 cases. Furthermore, the long-term impact of COVID-19 is likely to add to the market' growth over the forecast period.
Global Microkeratome Market: Key Developments
In August 2025, LENSAR, Inc., a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, announced the first commercial cases performed with ALLY Adaptive Cataract Treatment System by Robert Weinstock, MD at The Eye Institute of West Florida, U.S. Dr. Weinstock performed 15 laser-assisted cataract surgery cases following the recent installation of ALLY System.